Retraction: Zoledronic acid restores doxorubicin chemosensitivity and immunogenic cell death in multidrug- resistant human cancer cells (PLoS ONE (2013) 8:4 (e60975) DOI: 10.1371/journal.pone.0060975);Zoledronic Acid Restores Doxorubicin Chemosensitivity and Immunogenic Cell Death in Multidrug-Resistant Human Cancer Cells

PLoS ONE

Volumn 8, Issue 4, 2013, Pages

  Riganti, Chiara ^a,b   Castella, Barbara ^b   Kopecka, Joanna ^a   Campia, Ivana ^a   Coscia, Marta ^b   Pescarmona, Gianpiero ^a,b   Bosia, Amalia ^a,b   Ghigo, Dario ^a,b   Massaia, Massimo ^b  

^a UNIVERSITY OF TURIN   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MEVALONIC ACID; MULTIDRUG RESISTANCE PROTEIN; RAS PROTEIN; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; ZOLEDRONIC ACID;

ARTICLE; CANCER CELL; CD4+ T LYMPHOCYTE; CELL DEATH; CELL PHAGOCYTOSIS; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DRUG CYTOTOXICITY; DRUG MECHANISM; DRUG SENSITIVITY; DRUG TARGETING; HUMAN; HUMAN CELL; IMMUNOGENIC CELL DEATH; IMMUNOGENICITY; MULTIDRUG RESISTANCE; PROTEIN EXPRESSION; PROTEIN PRENYLATION; SIGNAL TRANSDUCTION;

EID: 84876092563     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0244194     Document Type: Erratum

References (45)

1. Swanson KM, Hohl RJ, (2006) Anti-Cancer Therapy: Targeting the Mevalonate Pathway. Curr Cancer Drug Targets 6: 15-37.
2. Clendening JW, Pandyra A, Boutrosa PC, El Ghamrasni S, Khosravi F, et al. (2010) Dysregulation of the mevalonate pathway promotes transformation. Proc Natl Acad Sci 107: 15051-15056.
3. Freed-Pastor WA, Mizuno H, Zhao X, Langerød A, Moon S-H, et al. (2012) Mutant p53 disrupts mammary tissue architecture via the mevalonate pathway. Cell 148: 244-258.
4. Gottesman MM, Fojo T, Bates SE, (2002) Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2: 48-58.
5. Troost J, Lindenmaie J, Haefeli WE, Weiss J, (2004) Modulation of cellular cholesterol alters P-glycoprotein activity in multidrug-resistant cells. Mol Pharmacol 66: 1332-1339.
6. Schmidmaier R, Baumann P, Simsek M, Dayyani F, Emmerich B, et al. (2004) The HMG-CoA reductase inhibitor simvastatin overcomes cell adhesion mediated drug resistance (CAM-DR) in multiple myeloma by geranylgeranylation of Rho protein and activation of Rho kinase. Blood 104: 1825-1832.
7. Riganti C, Orecchia S, Pescarmona GP, Betta PG, Ghigo D, et al. (2006) Bosia A. Statins revert doxorubicin resistance via nitric oxide in malignant mesothelioma. Int J Cancer 119: 17-27.
8. Mattarollo SR, Loi S, Duret H, Ma Y, Zitvogel L, et al. (2011) Pivotal Role of Innate and Adaptive Immunity in Anthracycline Chemotherapy of Established Tumors. Cancer Res 71: 4809-4820.
9. Obeid M, Tesniere A, Ghiringhelli F, Fimia GM, Apetoh L, et al. (2007) Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med 13: 54-61.
10. Apetoh L, Mignot G, Panaretakis T, Kroemer G, Zitvogel L, (2008) Immunogenicity of anthracyclines: moving towards more personalized medicine. Trends Mol Med 14: 141-151.
11. De Boo S, Kopecka J, Brusa D, Gazzano E, Matera L, et al. (2009) iNOS activity is necessary for the cytotoxic and immunogenic effects of doxorubicin in human colon cancer cells. Mol Cancer 8: e108.
12. Clézardin P, Massaia M, (2010) Nitrogen-containing bisphosphonates and cancer immunotherapy. Curr Pharm Des 16: 3007-3014.
13. Coscia M, Quaglino E, Iezzi M, Curcio C, Pantaleoni F, et al. (2010) Zoledronic acid repolarizes tumor-associated macrophages and inhibits mammary carcinogenesis by targeting the mevalonate pathway. J Cell Mol Med 14: 2803-2815.
14. Fiore F, Castella B, Nuschak B, Bertieri R, Mariani S, et al. (2007) Enhanced ability of dendritic cells to stimulate innate and adaptive immunity on short-term incubation with zoledronic acid. Blood 10: 921-927.
15. Castella B, Riganti C, Fiore F, Pantaleoni F, Canepari ME, et al. (2011) Immune modulation by zoledronic acid in human myeloma: an advantageous cross-talk between Vγ9Vδ2 T cells, αβ CD8+ T cells, regulatory T (Treg) cells, and dendritic cells. J Immunol 187: 1578-1590.
16. Castella B, Vitale C, Coscia M, Massaia M, (2011) Vγ9Vδ2 T cell-based immunotherapy in hematological malignancies: from bench to bedside. Cell Mol Life Sci 68: 2419-2432.
17. Morgan C, Lewis PD, Jones RM, Bertelli G, Thomas GA, et al. (2007) The in vitro anti-tumor activity of zoledronic acid and docetaxel at clinically achievable concentrations in prostate cancer. Acta Oncol 46: 669-677.
18. Ottewell PD, Lefley DV, Cross SS, Evans CA, Coleman RE, et al. (2009) Sustained inhibition of tumor growth and prolonged survival following sequential administration of doxorubicin and zoledronic acid in a breast cancer model. Int J Cancer 126: 522-532.
19. Coleman RE, Winter MC, Cameron D, Bell R, Dodwell D, et al. (2010) The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumor response: exploratory evidence for direct anti-tumor activity in breast cancer. Br J Cancer 102: 1099-1105.
20. Riganti C, Miraglia E, Viarisio D, Costamagna C, Pescarmona G, et al. (2005) Nitric Oxide reverts the resistance to doxorubicin in human colon cancer cells by inhibiting the drug efflux. Cancer Res 65: 516-525.
21. Kopecka J, Campia I, Olivero P, Pescarmona G, Ghigo D, et al. (2011) A LDL-masked liposomal-doxorubicin reverses drug resistance in human cancer cells. J Contr Rel 149: 196-205.
22. Riganti C, Pinto H, Bolli E, Belisario DC, Calogero RA, et al. (2011) Atorvastatin modulates anti-proliferative and pro-proliferative signals in Her2/neu-positive mammary cancer. Biochem Pharmacol 82: 1079-1089.
23. Laufs U, Liao JK, (2000) Targeting Rho in cardiovascular disease. Circ Res 87: 526-528.
24. Doublier S, Belisario DC, Polimeni M, Annaratone L, Riganti C, et al. (2012) HIF-1 activation induces doxorubicin resistance in MCF7 3-D spheroids via P-glycoprotein expression: a potential model of the chemo-resistance of invasive micropapillary carcinoma of the breast. BMC Cancer 12: e4.
25. Kopecka J, Campia I, Brusa D, Doublier S, Matera L, et al. (2011) Nitric oxide and P-glycoprotein modulate the phagocytosis of colon cancer cells. J Cell Mol Med 15: 1492-1504.
26. Betts MR, Brenchley JM, Price DA, De Rosa SC, Douek DC, et al. (2003) Sensitive and viable identification of antigen-specific CD8+ T cells by a flow cytometric assay for degranulation. J Immunol Meth 281: 65-78.
27. Stresing V, Daubiné F, Benzaid I, Monkkonen H, Clèzardin P, (2007) Bisphosphonates in cancer therapy. Cancer Lett 257: 16-35.
28. Daubiné F, Le Gall C, Gasser J, Green J, Clézardin P, (2007) Antitumor effects of clinical dosing regimens of bisphosphonates in experimental breast cancer bone metastasis. J Natl Cancer Inst 99: 322-330.
29. O'Donnell JL, Joyce MR, Shannon AM, Harmey J, Geraghty J, et al. (2006) Oncological implications of hypoxia inducible factor-1a (HIF-1a) expression. Cancer Treat Rev 32: 407-416.
30. Takata K, Morishige K, Takahashi T, Hashimoto K, Tsutsumi S, et al. (2008) Fasudil-induced hypoxia-inducible factor-1alpha degradation disrupts a hypoxia-driven vascular endothelial growth factor autocrine mechanism in endothelial cells. Mol Cancer Ther 7: 1551-1561.
31. Sharma V, Dixit D, Koul N, Mehta VS, Sen E, (2011) Ras regulates interleukin-1β-induced HIF-1α transcriptional activity in glioblastoma. J Mol Med 89: 123-136.
32. Zappasodi R, Pupa SM, Ghedini GC, Bongarzone I, Magni M, et al. (2010) Improved clinical outcome in indolent B-cell lymphoma patients vaccinated with autologous tumor cells experiencing immunogenic death. Cancer Res 70: 9062-9072.
33. Pallottini V, Guantario B, Martini C, Totta P, Filippi I, et al. (2008) Regulation of HMG-CoA Reductase Expression by Hypoxia. J Cell Biochem 104: 701-709.
34. Rohwer N, Cramer T, (2011) Hypoxia-mediated drug resistance: novel insights on the functional interaction of HIFs and cell death pathways. Drug Resist Updat 14: 191-201.34.
35. Eckford PDW, Sharom FJ, (2008) Interaction of the P-Glycoprotein Multidrug Efflux Pump with Cholesterol: Effects on ATPase Activity, Drug Binding and Transport. Biochemistry 47: 13686-13698.
36. Sieczkowski E, Lehner C, Ambros PF, Hohenegger M, (2010) Double impact on p-glycoprotein by statins enhances doxorubicin cytotoxicity in human neuroblastoma cells. Int J Cancer 126: 2025-2035.
37. Connelly-Smith L, Pattinson J, Grundy M, Shang S, Seedhouse C, et al. (2007) P-glycoprotein is downregulated in KG1a-primitive leukemia cells by LDL cholesterol deprivation and by HMG-CoA reductase inhibitors. Exp Hematol 35: 1793-1800.
38. Matsumoto S, Kimura S, Segawa H, Kuroda J, Yuasa T, et al. (2005) Efficacy of the third-generation bisphosphonate, zoledronic acid alone and combined with anti-cancer agents against small cell lung cancer cell lines. Lung Cancer 47: 31-39.
39. Pluchino KM, Hall MD, Goldsborough AS, Callaghan R, Gottesman MM, (2012) Collateral sensitivity as a strategy against cancer multidrug resistance. Drug Resist Updat 15: 98-105.
40. Shukla A, Hillegass JM, MacPherson MB, Beuschel SL, Vacek PM, et al. (2010) Blocking of ERK1 and ERK2 sensitizes human mesothelioma cells to doxorubicin. Mol Cancer 9: e314.
41. Ottewell PD, Mönkkönen H, Jones M, Lefley DV, Coleman RE, et al. (2008) Antitumor Effects of Doxorubicin Followed by Zoledronic Acid in a Mouse Model of Breast Cancer. J Natl Cancer Inst 100: 1167-1178.
42. Zitvogel L, Kepp O, Kroemer G, (2011) Immune parameters affecting the efficacy of chemotherapeutic regimens. Nat Rev Clin Oncol 8: 151-160.
43. Kooij G, Backer R, Koning JJ, Reijerkerk A, van Horssen J, et al. (2009) P-Glycoprotein acts as an immunomodulator during neuroinflammation. PLoSOne 4: e8212.
44. Takara K, Sakaeda T, Okumura K, (2006) An update on overcoming MDR1-mediated multidrug resistance in cancer chemotherapy. Curr Pharm Des 12: 273-286.
45. Türk D, Hall MD, Chu BF, Ludwig JA, Fales HM, et al. (2009) Identification of compounds selectively killing multidrug-resistant cancer cells. Cancer Res 69: 8293-8301.